Compare TIL & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIL | GSIW |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 42.6M |
| IPO Year | 2021 | 2022 |
| Metric | TIL | GSIW |
|---|---|---|
| Price | $7.18 | $26.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $125.00 | N/A |
| AVG Volume (30 Days) | 10.3K | ★ 10.4K |
| Earning Date | 05-08-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $0.05 |
| 52 Week High | $33.83 | $38.55 |
| Indicator | TIL | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 38.09 |
| Support Level | $6.85 | $0.11 |
| Resistance Level | $8.30 | $33.00 |
| Average True Range (ATR) | 0.19 | 1.43 |
| MACD | -0.02 | -0.43 |
| Stochastic Oscillator | 21.05 | 0.00 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.